RP Bio Inc. (KOSDAQ:314140)

South Korea · Delayed Price · Currency is KRW

5,980.00

-90.00 (-1.48%)

At close: Sep 11, 2026

RP Bio Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	141,425	136,219	123,967	151,046	138,109	114,964
Revenue Growth	9.55%	9.88%	-17.93%	9.37%	20.13%	17.40%
Gross Profit	16,427	13,812	7,184	15,560	17,754	12,912
Operating Income	7,469	5,084	-693.64	6,623	9,647	5,880
Net Income	6,726	4,682	-907.12	5,437	4,316	3,813
Earnings Per Share	777.28	541.31	-105.00	582.00	606.00	580.00
EPS Growth	121.17%	-	-	-3.96%	4.48%	-16.43%

Revenue by Segment

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Health Functional Food	71,858	85,991
Medicines	51,472	63,891
Raw Materials, etc.	332.92	910.98
Other	303.2	252.84

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	19,763	14,626	18,836	12,558	18,304	7,718
Total Debt	19,243	19,448	30,194	30,781	38,185	40,336
Net Cash (Debt)	519.88	-4,821	-11,359	-18,223	-19,881	-32,618
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	60.08	-557.39	-1314.76	-1950.62	-2791.65	-4962.17

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	11,915	12,476	13,524	10,580	1,155	9,459
Capital Expenditures	-3,872	-5,200	-5,853	-11,123	-5,147	-7,246
Free Cash Flow	8,043	7,276	7,670	-543.31	-3,992	2,213
Free Cash Flow Growth	10.90%	-5.14%	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	11.62%	10.14%	5.79%	10.30%	12.86%	11.23%
Operating Margin	5.28%	3.73%	-0.56%	4.38%	6.98%	5.12%
Pretax Margin	5.11%	3.40%	-0.98%	3.75%	4.10%	3.73%
Profit Margin	4.76%	3.44%	-0.73%	3.60%	3.13%	3.32%
FCF Margin	5.69%	5.34%	6.19%	-0.36%	-2.89%	1.93%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	7.69	13.70	-	13.79	23.75	-
P/FCF Ratio	6.44	8.81	5.71	-	-	-
PS Ratio	0.37	0.47	0.35	0.50	0.74	-